Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jörg Hendle

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Acta Crystallographica. Section D, Biological Crystallography|January 25, 2002
Reliable quality-control methods for protein crystal structuresJohn Badger, Jörg Hendle
Acta Crystallographica. Section D, Biological Crystallography|August 20, 2003
X-ray crystallographic characterization and phasing of an NtrC homologueLászló Sallai, Jörg Hendle, Paul A Tucker
Structure (London, England : 1993)|November 14, 2002
Structural studies of Salmonella typhimurium ArnB (PmrH) aminotransferase: a 4-amino-4-deoxy-L-arabinose lipopolysaccharide-modifying enzymeBrian W Noland, Janet M Newman, Jörg Hendle, et al.
Bioorganic & Medicinal Chemistry Letters|April 11, 2008
Fragment-based discovery of hepatitis C virus NS5b RNA polymerase inhibitorsStephen S Antonysamy, Brandon Aubol, Jeff Blaney, et al.
The Journal of Biological Chemistry|October 28, 2004
A novel mode of Gleevec binding is revealed by the structure of spleen tyrosine kinaseShane Atwell, Jason M Adams, John Badger, et al.
Nature|May 8, 2024
Discovery of potent small-molecule inhibitors of lipoprotein(a) formationNuria Diaz, Carlos Perez, Ana Maria Escribano, et al.
Alzheimer'S & Dementia (New York, N. Y.)|January 3, 2025
Discovery and clinical translation of ceperognastat, an O-GlcNAcase (OGA) inhibitor, for the treatment of Alzheimer's diseaseWilliam Kielbasa, Paul Goldsmith, Kevin B Donnelly, et al.
Bioorganic & Medicinal Chemistry|December 2, 2019
Preparation and biological evaluation of BACE1 inhibitors: Leveraging trans-cyclopropyl moieties as ligand efficient conformational constraintsLeonard L Winneroski, Jon A Erickson, Steven J Green, et al.
Journal of Medicinal Chemistry|June 3, 2021
Discovery and Early Clinical Development of LY3202626, a Low-Dose, CNS-Penetrant BACE InhibitorDavid L McKinzie, Leonard L Winneroski, Steven J Green, et al.
Cell Reports|May 14, 2022
LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variantsKathryn Westendorf, Stefanie Žentelis, Lingshu Wang, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Acta Crystallographica. Section D, Biological Crystallography|January 25, 2002
Reliable quality-control methods for protein crystal structuresJohn Badger, Jörg Hendle
Acta Crystallographica. Section D, Biological Crystallography|August 20, 2003
X-ray crystallographic characterization and phasing of an NtrC homologueLászló Sallai, Jörg Hendle, Paul A Tucker
Structure (London, England : 1993)|November 14, 2002
Structural studies of Salmonella typhimurium ArnB (PmrH) aminotransferase: a 4-amino-4-deoxy-L-arabinose lipopolysaccharide-modifying enzymeBrian W Noland, Janet M Newman, Jörg Hendle, et al.
Bioorganic & Medicinal Chemistry Letters|April 11, 2008
Fragment-based discovery of hepatitis C virus NS5b RNA polymerase inhibitorsStephen S Antonysamy, Brandon Aubol, Jeff Blaney, et al.
The Journal of Biological Chemistry|October 28, 2004
A novel mode of Gleevec binding is revealed by the structure of spleen tyrosine kinaseShane Atwell, Jason M Adams, John Badger, et al.
Nature|May 8, 2024
Discovery of potent small-molecule inhibitors of lipoprotein(a) formationNuria Diaz, Carlos Perez, Ana Maria Escribano, et al.
Alzheimer'S & Dementia (New York, N. Y.)|January 3, 2025
Discovery and clinical translation of ceperognastat, an O-GlcNAcase (OGA) inhibitor, for the treatment of Alzheimer's diseaseWilliam Kielbasa, Paul Goldsmith, Kevin B Donnelly, et al.
Bioorganic & Medicinal Chemistry|December 2, 2019
Preparation and biological evaluation of BACE1 inhibitors: Leveraging trans-cyclopropyl moieties as ligand efficient conformational constraintsLeonard L Winneroski, Jon A Erickson, Steven J Green, et al.
Journal of Medicinal Chemistry|June 3, 2021
Discovery and Early Clinical Development of LY3202626, a Low-Dose, CNS-Penetrant BACE InhibitorDavid L McKinzie, Leonard L Winneroski, Steven J Green, et al.
Cell Reports|May 14, 2022
LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variantsKathryn Westendorf, Stefanie Žentelis, Lingshu Wang, et al.
Pageof 2